Related Experiment Video
Updated: Jun 21, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
Published on: January 31, 2022
"In vitro" studies on the fate of diphenylhydantoin in uremia
Y Herishanu1, U Eylath, R Ilan
1Neurology Unit and Neurobiochemistry Clinical Laboratory, Shaare Zedek Hospital, Jerusalem, Israel.
Abstract:
"In vitro" studies were undertaken to evaluate the fate of DPH in blood of uremic patients. DPH incubated for 18 h at 37 degrees C disappears from plasma in the presence of erythrocytes and more when the blood underwent hemolysis. This phenomenon was more pronounced in uremic blood. These findings suggest not only that DPH is absorbed onto the erythrocyte membrane, but also that it is bound by erythrocyte contents. It could be possible that, because of a low binding capacity of the albumin carrier in uremic blood, the drug penetrates more easily the erythrocyte membrane and is bound there. An intraery throcyte enzymatic metabolism of DPH is not excluded.
Related Concept Videos
Drug Elimination by Renal Route: Tubular Reabsorption
Enhanced Elimination of Poison
Antidotes serve a crucial role in counteracting the effects of poison by inhibiting enzymes responsible for producing harmful drug metabolites. In some cases, these toxic metabolites can be neutralized by endogenous cosubstrates, which are maintained at specific concentrations to prevent interaction with cellular macromolecules and subsequent cell death.
Renal excretion is the...
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
Drug Elimination by Renal Route: Tubular Secretion
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Renal Drug Excretion: Tubular Reabsorption
